JPS6323176B2 - - Google Patents

Info

Publication number: JPS6323176B2
Authority: JP; Japan
Prior art keywords: type interferon; interferon; cells; type; sensitive disease
Prior art date: 1986-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP61100263A

Other languages

English (en)

Japanese (ja)

Other versions

JPS61263929A (ja

Inventor

Kaname Sugimoto

Shokichi Ketsuen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-04-30

Filing date

1986-04-30

Publication date

1988-05-16

1986-04-30 Application filed by Individual filed Critical Individual

1986-04-30 Priority to JP61100263A priority Critical patent/JPS61263929A/ja

1986-11-21 Publication of JPS61263929A publication Critical patent/JPS61263929A/ja

1988-05-16 Publication of JPS6323176B2 publication Critical patent/JPS6323176B2/ja

Status Granted legal-status Critical Current

Links

102000014150 Interferons Human genes 0.000 claims description 146
108010050904 Interferons Proteins 0.000 claims description 146
229940079322 interferon Drugs 0.000 claims description 145
241001465754 Metazoa Species 0.000 claims description 45
201000010099 disease Diseases 0.000 claims description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
239000003795 chemical substances by application Substances 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 15
238000000338 in vitro Methods 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 13
239000002799 interferon inducing agent Substances 0.000 claims description 13
241000486679 Antitype Species 0.000 claims description 11
229940124597 therapeutic agent Drugs 0.000 claims description 10
241000282412 Homo Species 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 7
210000001124 body fluid Anatomy 0.000 claims description 6
239000010839 body fluid Substances 0.000 claims description 6
238000009792 diffusion process Methods 0.000 claims description 6
210000004369 blood Anatomy 0.000 claims description 4
239000008280 blood Substances 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 2
239000004615 ingredient Substances 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
239000003381 stabilizer Substances 0.000 claims description 2
239000004067 bulking agent Substances 0.000 claims 1
239000006072 paste Substances 0.000 claims 1
210000004027 cell Anatomy 0.000 description 85
238000000034 method Methods 0.000 description 27
238000004519 manufacturing process Methods 0.000 description 17
238000002474 experimental method Methods 0.000 description 11
230000003612 virological effect Effects 0.000 description 11
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
230000016396 cytokine production Effects 0.000 description 8
235000015097 nutrients Nutrition 0.000 description 8
230000002265 prevention Effects 0.000 description 8
239000000047 product Substances 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
238000002054 transplantation Methods 0.000 description 8
241000699660 Mus musculus Species 0.000 description 7
241000700605 Viruses Species 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000011580 nude mouse model Methods 0.000 description 7
108010047620 Phytohemagglutinins Proteins 0.000 description 6
230000001885 phytohemagglutinin Effects 0.000 description 6
241000894007 species Species 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
241000699800 Cricetinae Species 0.000 description 5
241000711408 Murine respirovirus Species 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000003449 preventive effect Effects 0.000 description 5
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
206010003445 Ascites Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
230000035931 haemagglutination Effects 0.000 description 3
230000008105 immune reaction Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000004565 tumor cell growth Effects 0.000 description 3
-1 Since its discovery Proteins 0.000 description 2
102000016605 B-Cell Activating Factor Human genes 0.000 description 2
108010028006 B-Cell Activating Factor Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
238000011047 acute toxicity test Methods 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000006698 induction Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000007923 nasal drop Substances 0.000 description 2
229940100662 nasal drops Drugs 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
241000271566 Aves Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000005100 Herpetic Keratitis Diseases 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000282887 Suidae Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000012544 Viral Skin disease Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
210000001691 amnion Anatomy 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
238000005185 salting out Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
208000002254 stillbirth Diseases 0.000 description 1
231100000537 stillbirth Toxicity 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000005727 virus proliferation Effects 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

JP61100263A 1986-04-30 1986-04-30 抗タイプ２インターフェロン感受性疾患剤 Granted JPS61263929A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP61100263A JPS61263929A (ja)	1986-04-30	1986-04-30	抗タイプ２インターフェロン感受性疾患剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP61100263A JPS61263929A (ja)	1986-04-30	1986-04-30	抗タイプ２インターフェロン感受性疾患剤

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP454479A Division JPS5598118A (en)	1979-01-18	1979-01-18	Preparation of type-2 interferon and drug containing the same

Publications (2)

Publication Number	Publication Date
JPS61263929A JPS61263929A (ja)	1986-11-21
JPS6323176B2 true JPS6323176B2 (it)	1988-05-16

Family

ID=14269316

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP61100263A Granted JPS61263929A (ja)	1986-04-30	1986-04-30	抗タイプ２インターフェロン感受性疾患剤

Country Status (1)

Country	Link
JP (1)	JPS61263929A (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2039276T3 (es) *	1987-01-20	1993-09-16	Schering Corporation	Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5562024A (en) *	1978-10-31	1980-05-10	Hayashibara Takeshi	Preventive and remedy for interferon-sensitive disease

1986
- 1986-04-30 JP JP61100263A patent/JPS61263929A/ja active Granted

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5562024A (en) *	1978-10-31	1980-05-10	Hayashibara Takeshi	Preventive and remedy for interferon-sensitive disease

Also Published As

Publication number	Publication date
JPS61263929A (ja)	1986-11-21

Legal Events

Date	Code	Title	Description
2004-01-18	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JPS631296B2 (it)	1988-01-12
NL192086C (nl)	1997-02-04	Werkwijze ter bereiding van interferonen en werkwijze ter bereiding van een geneesmiddel dat interferonen bevat.
US4621050A (en)	1986-11-04	Process for the production of human colony-stimulating factor
JPS6045849B2 (ja)	1985-10-12	ヒトエリトロポエチンの製造方法
JPS6227048B2 (it)	1987-06-12
KR860000894B1 (ko)	1986-07-16	인체 인슐린의 제조방법
JPS6323176B2 (it)	1988-05-16
JPS6011890B2 (ja)	1985-03-28	ツモアネクロシスフアクタ−の製造方法
US4624917A (en)	1986-11-25	Process for the production of human T-cell growth factor
JPS6245208B2 (it)	1987-09-25
JP2926409B2 (ja)	1999-07-28	癌転移抑制因子の製造方法
JPH0214039B2 (it)	1990-04-05
JPS5823793A (ja)	1983-02-12	ヒトｔ細胞増殖因子の製造方法
KR970002165B1 (ko)	1997-02-24	γ-인터페론의 제조방법과 그 용도
KR820001174B1 (ko)	1982-06-29	사람 특이성 인터페론의 제조법
KR950008569B1 (ko)	1995-08-03	신규 림포카인(lymphokine) 및 그 제조방법과 사용방법
JPH0764744B2 (ja)	1995-07-12	標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
KR830001817B1 (ko)	1983-09-12	타이프ⅱ 인터페론의 제조방법
JP2532025B2 (ja)	1996-09-11	新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
JPH0446928B2 (it)	1992-07-31
JPS6045850B2 (ja)	1985-10-12	ヒト副腎皮質刺激ホルモンの製法
JP2850293B2 (ja)	1999-01-27	γ−インターフェロン感受性疾患剤
JP2518635B2 (ja)	1996-07-24	ヒトツモア・ネクロシス・フアクタ−
JPH0214038B2 (it)	1990-04-05
JPH0527640B2 (it)	1993-04-21